Stuart L. Goldberg, MD, On the Role of the Multidisciplinary Approach in Biomarker Testing

Article

The expert spoke about the importance of coordination to make sure every person involved with a patient’s care is in agreement as to how to treat the patient most effectively.

Stuart L. Goldberg, MD, from Hackensack University Medical Center, spoke with CancerNetwork® about the role that the multidisciplinary approach plays in biomarker testing and the importance of coordination in this setting. 

Transcription:

In order to do biomarkers, you have to coordinate and get the sample properly. Many of our patients with colon cancer, with lung cancer, they’re not seeing the oncologist first. The biopsies are being done by the pulmonologists, by the gastroenterologist, and those samples may then go to a pathologist who doesn’t think about the diagnosis, or if they get the diagnosis, they then fail to then talk to the oncologist early and send the samples off. And so, we need to coordinate between the primary care physician, the person who’s making the diagnosis at the tissue level, the pathologist who gets that sample, and the oncologist to make sure that everyone’s on the same page as to what type of genetic profiling needs to be done and how to do it in a cost effective manner. We don’t need to spend lots of money on tests that we’re not going to be doing if the patient’s not going to be getting therapy. But on the other hand, if the patient is going to be getting therapy, we want to make sure that all the right tests are being done. 

Related Videos
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Alexander Spira, MD, PhD, FACP, an expert on lung cancer
A panel of 4 experts on lung cancer
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.